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1. Introduction 
Renal biopsy in children can be performed either by percutaneous, laparoscopic, or open 
surgical approaches. As reported in a recent large pediatric series (Hussain et al., 2010), the 
percutaneous approach is by far the most commonly utilized, with the open approach 
typically reserved for situations in which percutaneous biopsy may be relatively 
contraindicated or there is the need for a large wedge of tissue. Increasingly, more centers 
are reporting successful experience with laparoscopic approaches as an alternative to open 
surgical biopsies (Caione et al., 2000; Luque Mialdea et al., 2006; Mukhtar et al., 2005). 
Native renal biopsy should be performed in a child when kidney disease is suspected and 
treatment decisions require confirmation, when staging or characterization of a known 
kidney disease is warranted, or when the disease diagnosis is known but the utility of 
further treatment is questioned. In contrast to adults, renal insufficiency in children is 
more often secondary to sequelae from congenital or structural anomalies rather than 
acquired diseases. As a result, loss of renal function is not unexpected and tends to 
progress more slowly. Typically, children with such well-defined renal anomalies do not 
undergo biopsy even as renal function declines, unless a new entity is thought to be 
present.  
On the other hand, children presenting with an acquired kidney condition, especially with 
rapidly changing renal function or lack of response to empiric therapy, do require renal 
biopsy to allow for accurate diagnosis and tailoring of therapeutic intervention. Moreover, 
while relatively common medical conditions such as hypertension and diabetes mediate 
much of the chronic kidney disease seen in adults, these conditions are rarer in children and 
less likely to impact renal health in the pediatric patient, leading to a need for clinicians to 
actually identify why kidney disease has arisen in the child. 
In contrast to many adults, children and adolescents typically require significant 
conscious sedation or even general anesthesia for successful renal biopsy. Consequently, 
the risks of both the procedure and sedation/anesthesia must be considered when 
determining whether to do the biopsy. There are several medical conditions that often 
preclude biopsy. Although each case must be individually considered and there may be 
an occasion when the information garnered at biopsy outweighs the potential risk, the 
following situations are often considered contraindications or relative contraindications 
for pediatric biopsy:  
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Contraindications for biopsy: 
- Severe bleeding disorders such as hemophilia 
- Known abdominal malignancy 
- Multiple renal cysts or renal tumor preventing sampling of renal parenchyma 
- Compromised skin or skin infection overlying biopsy entry site 
- Uncontrolled hypertension, increasing the risk of post-operative bleeding 
Relative Contraindications: 
- Massive ascites 
- Severe hydronephrosis 
While some have challenged the safety of performing renal biopsy in a child with a solitary 
kidney, current complication rates have decreased to such a degree that, if warranted for 
diagnostic reasons and if being performed by experienced clinicians utilizing medical 
imaging to visualize the kidney during biopsy, this is generally not considered to be a 
contraindication.  
2. Nuts and bolts: Logistics of planning and preparation for the biopsy 
procedure 
If no ultrasound has been obtained in the past or if there is concern that there may have been 
an interval change in the kidney or urinary tract anatomy since the last imaging study, a 
renal ultrasound is performed to assess for anomalies such as hydronephrosis, to confirm 
location and number of kidneys, and to assess renal size prior to the biopsy. The point of the 
ultrasound is to identify any anatomic reason why biopsy would be contraindicated or that 
would alter the approach to the biopsy. 
A complete blood count (CBC), coagulation panel including prothrombin time (PT) and 
partial thromboplastin time (PTT), as well as a sample for type and screen to be held in the 
blood bank are obtained, typically within 72 hours of the procedure. The CBC allows 
baseline hematologic parameters to be ascertained in case there is concern regarding 
bleeding or infection post-procedure and also confirms an acceptable platelet count prior to 
an invasive procedure. The PT/PTT identifies any tendency toward a coagulopathy that 
may increase the chances of a bleeding complication. Although transfusion post-biopsy is 
rare, having a blood type and screen in the blood bank will expedite this process if it is 
necessary, and especially if it is urgently required. 
Informed consent is obtained from either the parent/guardian or the patient if the patient is 
of legal age. The consent process must include explaining the risks of the procedure, 
however rare, including bleeding, infection, and the potential need for surgery to control 
bleeding or perform nephrectomy. In children less than 18 years of age who are cognitively 
capable of understanding the rationale for the biopsy procedure, in addition to informed 
consent from the parent or legal guardian, there is utility in obtaining assent from the child. 
This documents that the patient was also involved in the decision to proceed with the 
biopsy and underscores the need to keep the patient involved in a developmentally 
appropriate fashion with the process.  
Prior to the biopsy, the patient will need to fast for some period of time, depending on 
whether sedation or anesthesia is being utilized and institutional protocols. Most children 
should tolerate this period of time without the need for supplemental intravenous 
hydration, but individual circumstance and clinical status must be reviewed to determine if 
the usual period of fasting is likely to cause any untoward consequence; for instance, a child 
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with diabetes insipidus or a child with a severe urinary concentrating defect would require 
special hydration plans. 
3. Nuts and bolts: Sedation or anesthesia for the pediatric renal biopsy 
Local standards and individual clinician preference have the greatest impact on the type of 
sedation or anesthesia for pediatric patients undergoing percutaneous renal biopsy. The 
overwhelming majority of children are offered intravenous conscious sedation or some sort 
of general anesthesia, with very few patients declining such measures and opting for local 
anesthesia injected at the biopsy site alone.  In rare cases of children with serious 
contraindication or objection to sedation or anesthesia, ‘’verbal sedation’’ has been used, 
with the child talked through the procedure with the help of a child life specialist trained in 
this approach (Hussain et al., 2003). 
Case series from North American centers show that general anesthesia is most often 
reserved for infants or very small children where lack of cooperation during the procedure 
is a concern as well as in children whose airways may be at risk with sedation alone (Birk et 
al., 2007; Simckes et al., 2000; Sweeney et al., 2006). This approach is not necessarily the case 
worldwide and, in fact, a recent audit in the United Kingdom (Hussain et al., 2010) showed 
6 of 11 centers routinely using general anesthesia for pediatric kidney biopsies. 
Intravenous ‘’conscious’’ sedation, sometimes termed ‘’deep’’ procedural sedation, is usually 
administered by a nurse or physician who has acquired expertise in various sedation 
techniques and certification in pediatric advanced life support (Cravero et al., 2006; Mason et 
al., 2009). The patients should receive continuous cardiorespiratory monitoring throughout the 
procedure. A variety of agents may be utilized and the protocols are institution specific or 
dependent on local resources.  
Our institution has successfully employed a radiologist-supervised ketamine sedation protocol 
for many solid organ biopsies (Mason et al., 2009). In this protocol, children receive an IV 
Ketamine bolus (2 mg/kg) over a 5-minute period with concomitant administration of 0.005 
mg/kg of IV glycopyrolate. The bolus of ketamine is immediately followed by a continuous 
infusion of 25-150 mcg/kg/min of ketamine for the duration of the procedure. Patients older 
than 5 years also receive 0.1 mg/kg of midazolam hydrochloride (maximum = 3mg) before the 
initial bolus of ketamine. There have been no major adverse events reported with this protocol 
and both patient and family satisfaction rates have been high.  
Other published sedation protocols employ a combination of meperidine (1 mg/kg– 
maximum 50 mg) and diazepam (0.2-0.4 mg/kg), with ketamine reserved for additional 
sedation if necessary (Hussain et al., 2003); midazolam 0.1 mg/kg with additional ketmaine 
where required (Mahajan et al., 2010); or intravenous propofol (1 mg/kg/dose titrated to 
effect) and fentanyl (1 µg/kg/dose) (Birk et al., 2007). Again, local practice and clinician 
familiarity and expertise with certain medications tend to influence the type of sedation 
provided most successfully and is more critical than the use of any specific medication or 
combination of medications. 
Local anesthesia may be achieved by applying a topical anesthetic cream (EMLA, lidocaine 
2.5% and pritocaine 2.5% or Ametop tetracaine 4%) (Hussain et al., 2003) or local infiltration 
with 1% lidocaine. At our center, for local infiltration with lidocaine, 9 mls of lidocaine  
are mixed with 1 ml of 8.4% sodium bicarbonate; this approach seems to decrease 
complaints of burning at the site of infiltration, and this is employed regardless of the type 
of sedation utilized. 
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The majority of percutaneous renal biopsies performed under sedation are done outside the 
operating room, usually in an interventional radiology suite, a procedure area with access to 
ultrasound imaging, or in ward treatment rooms (Davis et al., 1998; Hussain et al., 2003; 
Mason et al., 2009). Although there were initial concerns about providing sedation in such 
settings for invasive procedures, our own experience and that of others have shown few 
safety concerns. The Pediatric Sedation Research Consortium reported a large series of 
30,037 sedation encounters from 26 centers, with data submitted on a variety of pediatric 
procedures performed under sedation or anesthesia outside the operating room (Cravero et 
al., 2006). This study demonstrated the overall safety of such procedures, with no deaths 
and only one cardiopulmonary resuscitation event. The most commonly encountered 
adverse event in this cohort was more than 30 seconds of oxygen desaturation to less than 
90% by transcutaneous monitoring, and this only occurred in 1.5% of cases. Needless to say, 
the safety and success of such programs depend on consistently following well-developed 
protocols, the presence of certified providers throughout the procedure, and readily 
available anesthesia services to handle unexpected complications. 
4. Nuts and bolts: Performing the renal biopsy 
As discussed above, institutional practice and resources often guide the location for 
pediatric biopsies. For instance, in our center, biopsies are performed in an Interventional 
Radiology suite with either nurses providing conscious sedation by protocol or Pediatric 
Anesthesiologists providing general anesthesia. The use of sedation versus anesthesia 
typically depends on the age of the patient, developmental and emotional factors, and any 
co-morbid medical conditions. For instance, a very young child with nephrotic syndrome 
and significant volume overload will likely warrant general anesthesia whereas a mature 
adolescent undergoing a transplant biopsy may need little other than local anesthesia over 
the biopsy site.  
Biopsies are performed under sterile conditions. As a result, it is important for the 
individual performing the biopsy to follow standard protocol for a sterile invasive 
procedure including aseptic technique and wearing appropriate gowns, gloves, masks, and 
eye protection.  
Obtaining an adequate sample is crucial for any renal biopsy, but is even more imperative in 
children undergoing biopsy where the logistics of the procedure may be more complicated. 
Availability of a dissecting microscope to view each core obtained to assess tissue adequacy 
is extremely useful to guide the number of cores needed. Presence of either a pathologist or 
nephrologist experienced in identifying renal tissue under dissecting microscope is 
obviously essential and should allow some estimation of tissue adequacy. 
For a native renal biopsy, the child is placed in a prone position and typically the left kidney 
is imaged to discern an acceptable biopsy site. In a transplant patient, the child will be 
supine and the area immediately over the allograft is imaged. The skin overlying the area 
most appropriate for biopsy needle introduction is marked during this process. Generally, a 
site in the lower pole of the kidney is selected, away from the renal hilum and large vessels. 
At this point, prior to proceeding further with the procedure, a pause or “time-out” is 
worthwhile, with the individual performing the procedure reviewing aloud the patient’s 
name, medical diagnosis, planned procedure including site of biopsy, and confirming that 
informed consent has been obtained. All others in the procedure area should then verbally 
identify themselves and their role in the procedure, for instance “Jane Jones, RN performing 
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sedation” or “John Smith, attending radiologist” so that there is both acknowledged 
consensus of the procedure to be done by all involved and understanding of the specific 
roles of all the individuals present in the area.  
The biopsy area is cleaned thoroughly with a betadine solution, and all areas outside the 
sterile field are covered with sterile drapes. A local anesthetic such as lidocaine is injected at 
the marked skin site. An initial wheal is made and then deeper infiltration performed, 
following the anticipated path of the biopsy needle. A superficial dermatotomy is made over 
the wheal, and the biopsy needle is advanced through this area.  
Typically, most pediatric renal biopsies are now done with ultrasound guidance. If desired, 
this allows use of a needle guide that helps to position the path of the biopsy needle along 
the desired biopsy tract. It also allows for continuous monitoring of the position of the 
needle during the procedure and allows for ready identification of structures such as bowel 
or large vessels that must be avoided. Optimally, the individual performing the biopsy has 
been trained in biopsy sonography as well, so that the same individual is controlling the 
imaging and the needle placement; otherwise, there needs to be continuous communication 
between the individual advancing the biopsy needle and the sonographer to be sure that 
both agree as to the needle position and the target.  
Local practice and available resources will determine the biopsy devices and needles used, 
most of which are readily available from medical vendors. For most percutaneous pediatric 
renal biopsies at our center, we use an 18-gauge needle and an automated biopsy device or 
“gun” that is loaded with the needle. The desired “throw” -- or length of the biopsy needle 
that gets propelled into the kidney when the device is engaged -- depends on the size of the 
child and the size of the kidney being biopsied. For most children, a throw of approximately 
2 centimeters allows for a safe biopsy with sufficient tissue but, in especially young children 
or with small kidneys, a shorter throw may be needed to avoid the renal hilum or other 
surrounding structures.   
The needle is advanced to the selected site in the lower pole renal cortex under continuous 
ultrasound guidance. Once the needle reaches the renal capsule, it is advanced slightly 
further to enter kidney tissue. The biopsy device is then “fired” which allows the inner 
hollow-core biopsy needle to deploy, cutting a piece of kidney tissue. The cutting needle is 
then automatically ensheathed by an outer protective core. The entire biopsy needle device 
is withdrawn from the kidney and the protective sheath withdrawn to expose the tissue 
core. The biopsy sample is carefully transferred onto a saline-soaked gauze by rolling the 
needle onto the gauze, and then the core is examined by the pathologist or nephrologist 
under a dissecting microscope for quick estimation of tissue adequacy. During this time 
following needle extraction, the physician performing the biopsy or another designee 
applies pressure to the biopsy site.  
This procedure is repeated until adequate renal tissue has been obtained for the biopsy 
indication, depending on the patient’s medical condition and the studies to be performed on 
the tissue. Typically, for native kidney biopsies, we obtain three cores of tissue to allow for 
sufficient tissue for light microscopy, immunofluorescence, and electron microscopy. For 
transplant biopsies, two cores are generally obtained since fewer studies are usually done. 
As always, the size and adequacy of tissue cores obtained will specifically define the 
number of cores needed for any patient. If adequate tissue is not obtained after three to five 
passes of the needle, then there must be consideration of the risk of ongoing passes into the 
kidney versus the benefits of obtaining more kidney tissue at this point in time.  
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At completion of the entire biopsy procedure, pressure is applied externally over the biopsy 
site for a minimum of 5 minutes. A post-biopsy ultrasound with Doppler imaging is then 
performed to evaluate for any hematoma or active bleeding. If bleeding is observed, 
pressure is maintained until there is evidence of stable imaging with no expanding 
hematoma or determination is made that there needs to be some other intervention. The 
dermatotomy site is covered with a sterile dressing that may be removed the following day. 
This dressing is observed for any bleeding or drainage while it is in place.   
5. Open renal biopsy in children 
Rarely, an open renal biopsy is appropriate in children. Common indications for open renal 
biopsy are listed in Table One. Some clinical scenarios where open biopsy is more common 
include when attempts at a percutaneous biopsy have failed, when a wedge resection is 
required for pathologic diagnosis, or when there is a bleeding disorder but the biopsy is 
paramount to treatment decisions. Open biopsy is performed typically by a general surgeon, 
urologist, or transplant surgeon in an operating room. Open renal biopsy will usually result 
in exposure to general anesthesia or more prolonged sedation with longer post-procedure 
recovery times, hence increasing health care delivery costs.  
 
• Failed percutaneous renal biopsy 
• Percutaneous renal biopsy deemed unsafe: 
• Uncontrolled hypertension 
• Bleeding disorder 
• Solitary native kidney with specific concerns for percutaneous approach 
• Anatomic abnormalities complicating percutaneous approach: 
• Horseshoe kidney 
• Pelvic kidney 
• Intraperitoneal renal allograft with specific concerns for percutaneous approach 
• Donor implantation biopsy at time of transplant 
• Biopsy performed concurrent with other surgical intra-abdominal procedure 
• Morbid obesity 
Table 1. Common Indications for Open Renal Biopsy 
There may be center-specific variation in the use of open biopsy depending on local 
experience and expertise. Similarly, there may be changes in local practice regarding specific 
clinical scenarios that may come to decrease the need for open renal biopsy. For instance, 
several centers have published their experiences transitioning from open to percutaneous 
biopsies of solitary kidneys and transperitoneal allografts (Mendelssohn & Cole, 1995; 
Vidhun et al., 2003). In cases that may be considered higher risk for percutaneous approach, 
most clinicians think it judicious to pay special attention to coagulation parameters, blood 
pressures and serum creatinine in determining the optimal approach for renal biopsy (Davis 
et al., 1998; Simckes et al., 2000). Similarly, in situations where a clinician is performing a 
higher risk percutaneous biopsy, it would be warranted to ensure in advance that there is 
availability of interventional radiology or surgical support services for unexpected 
complications. 
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6. Laparoscopic renal biopsy 
Within the last decade, there has also been increased utilization of laparoscopic approach as 
an alternative to traditional open biopsy. This approach has been well-established in 
morbidly obese adults where the body habitus precludes percutaneous approach (Mukhtar 
et al., 2005, as cited in Shetye et al., 2003). Unfortunately, obesity rates in children are at an 
all-time high and show no signs of abating (Anderson & Whitaker, 2009; Broyles et al., 2010). 
Obesity is also a frequent complication of steroid therapy commonly used in treating 
various glomerular lesions and in maintenance immunosuppression for renal transplant 
recipients who may come to require biopsy. Furthermore, in the face of the obesity 
epidemic, we are increasingly recognizing the entity of obesity-related secondary focal 
segmental glomerulosclerosis presenting with heavy proteinuria (Fowler et al., 2009). 
Consequently clinicians may find an increasing population of obese children requiring 
biopsy whose body habitus prevents a percutaneous approach.  
Mukhtar et al (Mukhtar et al., 2005) reported their experience with two morbidly obese 
children where initial attempts at percutaneous biopsy failed. The procedures were then 
carried out laparoscopically with no major complications, and both children were 
discharged home within 48 hours at significant cost savings compared to an open biopsy. 
Two larger case series from Italy and Spain (Caione et al., 2000; Luque Mialdea et al., 2006) 
also described successful experiences with laparoscopic renal biopsies in 20 and 53 pediatric 
patients, respectively. Children in those series ranged in age from 13 months to 19 years. 
The procedure was safe and successful in all but one patient in each series who required 
conversion to an open biopsy. The mean hospital stay in both cohorts was 48 hours or less. 
7. Differences between native and transplant biopsies in children 
In most children > 20 kg, transplanted kidneys are typically placed extraperitoneally in the 
lower abdomen within the iliac fossa. In smaller children, kidneys may need to be placed 
intraperitoneally. In most pediatric renal transplant recipients, transplanted kidneys are far 
more superficial than native kidneys and this must be kept in mind during biopsy to avoid 
improper sampling or damage to the vascular structures. Again, ultrasound guidance 
during the biopsy procedure will help to minimize these technical complications. In those 
children with intraperitoneal allografts, care must be taken to avoid bowel or other 
structures that may overlie the allograft.  
Allograft biopsies are typically performed to evaluate for acute rejection, to assess for 
recurrence of diseases such as Focal Segmental Glomerulosclerosis (FSGS), to define new 
onset suspected glomerular disease, to assess extent of chronic allograft nephropathy, or to 
document infectious insults such as BK virus nephropathy. Some centers may perform 
interval “protocol” biopsies at set intervals to assess the allograft parenchyma. Processing 
and staining of the biopsy samples from transplanted kidneys depends on the biopsy 
indication (see section 10).  
8. Post-biopsy monitoring in children 
There are currently no standard guidelines established for post renal biopsy monitoring. The 
standard of care in adult patients has included bed rest with close observation for up to 24 
hours (Whittier & Korbet, 2004). In their retrospective analysis of 750 adult patients who 
underwent native renal biopsy, Whittier and Korbet found an observation time of up to 24  
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hours to be optimal, with an observation period of 8 hours or less missing up to 33% of 
complications. There are, however, various clinical and social factors that impact any 
specific patient’s circumstances and, as a result, the length of observation post-biopsy 
should be somewhat individualized. 
In children, there are also wide variations in practice for post-biopsy monitoring. For 
instance, a survey of pediatric nephrologists in Japan (Kamitsuji et al., 1999) covering 
complications in 2,045 native percutaneous renal biopsies revealed that no center allowed 
discharge within 24 hours of the biopsy, with 67% of patients remaining in the hospital for 
at least 4-8 days. The patients in this cohort had similar complication rates to other pediatric 
series with shorter duration of observation, however, and the prolonged hospital stay was 
attributed to local practice.  
Over the last two decades, with increasing safety of percutaneous renal biopsy, particularly 
when performed with an automated biopsy needle under real time ultrasound guidance, 
more centers are moving towards short post-biopsy monitoring times for both native and 
allograft renal biopsies in children. In fact, several centers in North America and Europe 
have implemented same day renal biopsy in ambulatory or day clinical care units as 
standard practice for low risk patients since the early 1990s (Birk et al., 2007; Hussain et al., 
2003; Sweeney et al., 2006). This trend has been associated with significant cost savings 
compared to inpatient renal biopsies and comparable safety outcomes (Chesney et al., 1996; 
Hussain et al., 2003; Lau et al., 2009; Simckes et al., 2000). In addition, several centers in 
developing countries are reporting successful experiences with percutaneous renal biopsies 
in the ambulatory setting, where it was initially promoted for logistical reasons associated 
with limited inpatient bed space (Al Makdama & Al-Akash et al, 2006; Mahajan et al., 2010). 
In most centers where pediatric renal biopsies are performed as an inpatient procedure, 
there is consensus regarding the utility of bed rest in the supine position for a period of 3-6 
hours post biopsy. Patients are asked to save their urine for gross inspection and most 
centers allow the patient to stand to void if two consecutive post-biopsy urine samples are 
negative for gross hematuria. Vital signs are usually monitored every 15-30 minutes in the 
first 2 hours post biopsy and less frequently thereafter. Some centers provide intravenous 
hydration until patients are fully awake and able to drink. Most centers utilize 
acetaminophen for analgesia.  
Local standards often dictate post biopsy laboratory investigations or imaging studies. In 
our institution, biopsies are performed by nephrologists trained in renal sonography in the 
presence of an interventional radiologist who can immediately assist if there is some 
question or concern for an adverse event. As noted above, immediate post-biopsy images 
are also obtained by ultrasound to assess for hematoma formation and to provide a post-
biopsy baseline. Others employ routine post-biopsy ultrasound from 24 hours to two weeks 
following renal biopsy in all patients to detect peri/intra renal hematoma formation with 
consideration of Doppler studies to assess for arteriovenous fistula formation (Al Rasheed et 
al., 1990; Kamitsuji et al., 1999; Mahajan et al., 2010), though it is unclear whether this 
changes clinical care of the stable patient (Castoldi et al., 1994).  
It is also our practice to observe patients for at least 6 to 8 hours post-procedure and to check 
a hemoglobin and hematocrit level at 4-6 hours post biopsy and again the next morning as 
long as there is no concern to warrant repeat laboratory work sooner. A hematocrit drop of 
greater than 5-7%, severe abdominal or flank pain, gross hematuria that does not clear or 
markedly improve within two to three voids, or any evidence of hemodynamic instability 
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would prompt urgent renal imaging with an ultrasound to detect ongoing bleeding or 
expanding hematoma formation.  
In those centers that perform percutaneous renal biopsies in the ambulatory setting without 
provision for hospital admission, the selection criteria for low risk patients generally include 
normal or controlled blood pressure, normal pre-biopsy hematocrit and coagulation studies, 
a competent care giver to monitor the patient after the procedure, and the family’s 
willingness to stay within a reasonable distance of the hospital for the first night post-biopsy 
(Ogborn & Grimm, 1992). Following the biopsy, patients are typically monitored for 6-8 
hours with strict bed rest for 1-3 hours. Patients are discharged home at the end of this 
observation period if their urine is free of gross hematuria, their vital signs are stable and 
they have no significant pain at the biopsy site (Birk et al., 2007; Hussain et al., 2003; Ogborn 
& Grimm, 1992; Simckes et al., 2000). 
The value of routine post-biopsy imaging studies is controversial, with several studies 
suggesting the development of post biopsy perinephric hematomas is common and does not 
negatively impact patient outcomes or change the need for patient care in most cases 
(Castoldi et al., 1994; Vidhun et al., 2003). Detection of hematoma may also be a function of 
sensitivity of the imaging technique employed. For instance, data from CT scanning post 
biopsy reveals that perinephric hematoma is almost universal (Castoldi et al., 1994, as cited 
in Ralls et al., 1987). Castoldi et al further attempted to stratify hematomas according to size 
and correlate them with patient outcomes. In their retrospective analysis of 230 patients 
where 218 underwent post-biopsy sonography within 72 hours, the incidence of 
parenchymal, subcapsular, and perinephric hematomas combined was 42%. In the absence 
of clinical signs of bleeding, no short or long-term adverse effects were reported and, even 
in the presence of clinical signs of bleeding, serious complications only occurred in those 
with large hematomas. Large hematomas were defined as those having a thickness greater 
than 1 cm and length greater than 3 cm. Moreover, although these large hematomas were 
found in 20 patients (9% of their total cohort), only 7 of these patients had more than a 7% 
decrease in their post-biopsy hematocrit values. On the other hand, all hematomas with a 
thickness less than 2 cm in their study had a favorable clinical course.  
Davis et al (Davis et al., 1998) evaluated the utility of monitoring the post-biopsy change in 
hemoglobin concentration to identify bleeding complications that were otherwise not 
clinically apparent. In their retrospective review of 177 percutaneous renal biopsies (137 
native, 40 transplant), hemoglobin measurements were obtained at 4-10 hours and 15-24 
hours post biopsy. In their study, using a drop in hemoglobin levels of more than 16% of 
baseline – for instance from 10 g/dl to 8.4 g/dl -- served as a sensitive (100%) and specific 
(98%) marker of major bleeding complication that required either transfusion or additional 
monitoring. The change in post-biopsy hemoglobin was not associated with the presence of 
gross hematuria or perinephric hematoma, which were considered minor complications in 
this study. 
Children are allowed to return to school within one to two days of biopsy, though 
participation in physical education classes is usually avoided for one week. Children are 
also encouraged to avoid contact sports or vigorous activities that might result in direct 
trauma to the biopsy site for one week. Children are allowed to shower but immersion of 
the biopsy site in water is not recommended until the dermatotomy site is scabbed over, 
which typically occurs within 48 to 72 hours. In the immediate post-biopsy period, families 
are instructed to contact their pediatric nephrologist urgently for new onset gross 
hematuria, dysuria, pain at the biopsy site, or fever. 
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9. Complications post-biopsy 
Percutaneous renal biopsy as performed in most pediatric centers today with ultrasound 
guidance and automated biopsy needles is an extremely safe procedure with few associated 
minor and major complications. Those complications are summarized in Table 2. 
Various factors such as indication for biopsy, operator experience, needle type, and number 
of passes can affect the rate of post biopsy complications. In the large Japanese cohort of 
2,045 percutaneous native renal biopsies (Kamitsuji et al., 1999), the rate of gross hematuria 
was very low and comparable between patients in whom an automated biopsy needle was 
used compared to the older Vim-Silverman needle in which the cutting core was advanced 
manually (2.7% vs. 3%). On the other hand, in a retrospective analysis of 177 percutaneous 
renal biopsies, Davis et al (Davis et el., 1998) noted a significantly higher rate of post-biopsy 
hematoma in those procedures performed with an automated biopsy needle (Meditech 
ASAP Automatic 15-G Core Biopsy System needle) compared to a non-automated device (14 
G Franklin-Vim-Silverman needle or 15 G Trucut needle). However, the authors report the 
use of CT scan or ultrasound for post-biopsy imaging in the automated group compared to 
ultrasound only in the non-automated group, which might have led to increased detection 
of hematomas in the former because of CT’s higher sensitivity, rather than actual difference 
related to the biopsy device. Simckes et al (Simckes et al., 2000) found a trend for the non-
automated Trucut needle to be the least traumatic compared to the modified Franklin-Vim-
Silverman and automated spring-loaded needles in their cohort. In comparison, Webb et al 
(Webb et al., 1994) reported significantly more total complications with the Trucut needle 
compared to the automated biopsy needle, though the difference in major complications 
was not significant. Most likely, clinical factors and operator experience play a larger role in 
post-biopsy hematoma formation that the biopsy device itself. 
 
Minor complications Major complications 
• Microscopic hematuria 
• Self-limited gross hematuria 
• Asymptomatic peri-nephric hematoma 
• Asymptomatic decrease in Hb 
concentration 
• Self-limited arteriovenous fistula 
• Mild pain/ discomfort at biopsy site 
• Inadequate biopsy tissue and/ or 
failed biopsy 
 
• Persistent gross hematuria 
• Symptomatic peri-nephric hematoma 
causing hemodynamic instability 
• Significant decrease in Hb 
concentration requiring blood 
transfusion 
• Hypotension 
• Symptomatic arteriovenous fistula  
• Inadvertent damage to adjacent organs 
(e.g. liver, intestine) 
• Severe abdominal and/ or flank pain 
• Urinary tract infection 
• Urinary tract obstruction 
• Acute Renal Failure 
• Allograft loss 
• Nephrectomy 
• Death  
Table 2. Complications Post-Renal Biopsy  
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No difference has been reported in complication rates between using a 14-G Biopty gun 
needle or an automated 14-G Trucut needle, suggesting that needle size may influence the 
rate of complications more than needle type (Webb et al., 1994). Along those lines, Vidhun 
et al (Vidhun et al., 2003) have shown in renal allograft biopsies a higher incidence of 
perinephric hematoma (43% vs. 13.3%) and macroscopic hematuria (29% vs. 2.3%) with 
use of a 16-G versus an 18-G biopsy needle. Similar findings in native renal biopsies were 
also reported from a large Brazilian cohort (Piotto et al., 2008). As such, Birk et al (Birk et 
al., 2007) hypothesized that the slightly higher incidence of post-biopsy gross hematuria 
(8.4%) in their cohort of 43 renal transplant recipients compared to previously published 
reports (1.9-3.5%) was their use of a larger 16-G needle compared to an 18-G needle used 
elsewhere.  
With regards to other factors, several retrospective analyses have shown no significant 
difference in complication rates whether the biopsy was performed as an outpatient or 
inpatient procedure (Hussain et al., 2003, 2010; Simckes et al., 2000), under general 
anesthesia or sedation (Durkan et al., 2006; Hussain et al., 2010; Webb et al., 1994), by a 
supervised trainee or by an attending physician or consultant (Durkan et al., 2006; Simckes 
et al., 2000), and between an intraperitoneal and extraperitoneal graft in the case of allograft 
percutaneous biopsies (Vidhun et al., 2003). 
Interestingly, in native percutaneous biopsies, one author (Hussain et al., 2003) observed a 
trend for a higher incidence of gross hematuria post biopsy in those patients with a 
histological diagnosis of IgA Nephropathy/ Henoch-Schonlein Purpura. In the case of renal 
allografts, biopsies for urgent issues were noted to have a higher incidence of post biopsy 
hematoma compared to protocol biopsies (Vidhun et al., 2003). Increased number of passes 
was significantly associated with obtaining more adequate tissue for making a histological 
diagnosis (Durkan et al., 2006), but with a slightly increased but not significant trend 
towards hematoma formation (Simckes et al., 2000). 
Through the decades, the safety of percutaneous renal biopsy has been verified in several 
large pediatric case series. Death is extremely rare. One early review (Al Rasheed et al., 1990, 
as cited in White, 1963) reported 17 deaths in more than 10,000 biopsies (0.17%). Similarly, 
another large review at that time reported a mortality rate of 0.12% in 4000 biopsies 
(Simckes et al., 2000, as cited in Dodge et al., 1962). On the other hand, Edelmann found no 
deaths in a review of reports published between 1971-1976 of more than 1,700 percutaneous 
biopsies in children (Simckes et al., 2000, as cited in Edelmann et al., 1992). This improved 
safety profile continues to be reported in more recent series from North American and 
various institutions in Europe and Asia (Al Makdama & Al-Akash, 2006; Birk et al., 2007; 
Hussain et al., 2010; Kersnik Levart et al., 2001; Mahajan et al., 2010) and likely is mediated 
by concomitant imaging at the time of biopsy decreasing the chances for catastrophic 
hemorrhage or damage to vital organs other than the kidney. 
Given the use of different definitions and thresholds to report complications, it is worth 
noting, however, that rates of so-called minor and major complications post-biopsy are 
somewhat difficult to compare between individual centers. For example, one study included 
microscopic hematuria as a minor complication, a finding almost universally seen in all 
patients undergoing renal biopsy (Al Rasheed et al., 1990). Some studies include gross 
hematuria as a major complication, while others only include it if persistent and associated 
with hemodynamic instability and transfusion requirement. In their audit of UK centers, 
Hussain et al included 39 patients with gross hematuria in the major complication group 
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while only 4 of them required blood transfusions (Hussain et al., 2010). Regardless of those 
differences, most recent series report “major” complication rates in the 0-5% range and 
“minor” complications rates in the 8-15% range, though most complications that are 
reported in either category are of little immediate or long-lasting clinical significance to the 
patient’s well-being.  
Similar low complication rates also can be found with allograft biopsies. Benfield et al 
(Benfield et al., 1999) reported data from 19 pediatric transplant centers on 86 children who 
underwent 212 allograft biopsies. There were a total of 9 complications (4.2%) with only 4 
(1.9%) requiring intervention. No patient lost kidney function or required nephrectomy after 
graft biopsy. Vidhun et al (Vidhun et al., 2003) specifically analyzed complication rates in 
adult-sized renal allografts in children and reported an overall complication rate of 16.1%, 
consisting mostly of perinephric hematomas (13.4%), while the gross hematuria rate (2.7%) 
was similar to the cohort reported by Benfield. Most of those hematomas (81.4%) were small  
(< 1 cm), and no patient in that cohort required intervention related to post-biopsy 
complications. 
10. Pathologic findings 
The ultimate goal of the renal biopsy is to obtain sufficient tissue to make a diagnosis or guide 
therapy. Based on histologic assessment of the biopsy samples, therapeutic intervention may 
be initiated or altered and important prognostic information may be gained. 
It is crucial to obtain sufficient tissue to allow proper assessment by the pathologist. In certain 
pediatric renal diseases, light microscopy may be the most critical element, such as in the child 
with steroid resistant nephrotic syndrome in which the differential is minimal change disease 
versus focal and segmental glomerulosclerosis. In others, such as IgA nephropathy, 
immunofluorescence studies play a vital role and, in some, such as idiopathic 
membranoproliferative glomerulonephritis, electron microscopy will be necessary to 
supplement light microscopy and immunofluorescence results. Table Three summarizes the 
key pathologic studies to obtain on biopsy samples based on suspected clinical diagnosis. 
Table Four lists the histopathologic changes typically seen in several pediatric renal diseases. 
 
Suspected or Known 
Disease 
Light 
Microscopy 
Immunofluorescence Electron 
Microscopy 
IgA Nephropathy 
Henoch-Schonlein 
Purpura 
X 
Defines extent 
and severity of 
process 
X 
Necessary for 
diagnosis 
Suggested but not 
required 
Systemic Lupus 
Erythematosus 
X 
Necessary to 
identify 
class/severity 
X X 
Necessary to 
diagnose Class V 
(membranous) 
Membranoproliferative 
Glomerulonephritis 
X X X 
Necessary for 
diagnosis 
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Thin Basement 
Membrane Disease 
Hereditary Nephritis 
Alport’s 
Nail Patella Syndrome 
X X X 
Necessary for 
diagnosis 
Minimal Change 
Nephrotic Syndrome 
Focal and Segmental 
Glomerulosclerosis 
X X X 
ANCA associated 
vasculitis 
Anti-GBM disease 
Rapidly progressive 
glomerulonephritis 
X X ? May not be 
crucial 
Transplant Biopsies* X X **  
*If suspected recurrent disease, see above disease categories for tissue processing recommendations.  
** C4d crucial for diagnosis of acute antibody-mediated rejection 
Table 3. Desired Pathology Studies Based on Suspected Diagnosis 
 
Disease Light Microscopy Immunofluorescence Electron Microscopy 
Nephritis    
IgA Nephropathy 
 
 
Focal or diffuse 
mesangial 
hypercellularity 
 
Mesangial IgA deposits 
 
 
Focal mesangial 
proliferation with 
electron-dense 
subendothelial deposits 
Henoch-Schonlein Purpura Focal or diffuse 
mesangial 
hypercellularity, ± 
crescents 
Granular IgA  
 
Immune deposits 
Systemic Lupus 
Erythematosus 
   
   I: Minimal Mesangial Normal 
 
Mesangial immune 
deposits (Ig, C3, C4) 
 
Normal 
 
   II: Mesangial Proliferative 
 
Increased mesangial 
matrix 
Mesangial immune 
deposits (Ig, C3, C4) 
Few or no subepithelial 
or subendothelial 
deposits 
   III: Focal  
 
Less than 50% of 
glomeruli involved 
Mesangial deposits, few 
subepithelial and 
subendothelial deposits 
(Ig, C3, C4) 
Focal, subendothelial 
deposits 
   IV: Diffuse 
 
Nearly all glomeruli 
involved, wire-loop 
appearance- 
thickened BM 
Mesangial deposits, few 
subepithelial and 
subendothelial deposits 
(Ig, C3, C4) 
Endothelial cell 
proliferation 
Subendothelial immune 
complex deposition 
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   V: Membranous 
 
See membranous GN Subepithelial Ig, C3, C4 Subepithelial deposits 
   VI: Advanced Sclerosing ≥90% of glomeruli 
globally sclerosed 
  
Membranoproliferative 
Glomerulonephritis Type I 
Mesangial and 
endothelial cell 
proliferation, 
thickened basement 
membrane due to 
extensive immune 
complex deposition, 
increased mesangial 
matrix 
“Tram-track” or 
double-contour 
appearance of 
basement membrane 
(best seen with silver 
stain) 
Granular IgG and C3 
 
 
Mesangial Proliferation 
with immune deposits, 
subendothelial electron 
dense deposits between 
layers of BM double 
contours 
 
 
Membranoproliferative 
Glomerulonephritis Type II 
(Dense Deposit Disease) 
See MPGN Type I  C3 linear or double-
contoured along BM 
Subepithelial deposits- 
Electron dense deposits 
in ribbon-like pattern 
Thin Basement Membrane 
Disease 
Normal 
 
Normal Diffuse thinning of BM 
Alport’s  
 
Early: Normal 
Late: Sclerosis 
Negative Split basement 
membrane 
Post-Infectious 
Glomerulonephritis 
Enlarged glomeruli 
Endocapillary 
proliferation 
Obliteration of 
capillary loops 
Increased mesangial 
cells 
“Exudative 
proliferative GN” 
Irregular granular C3, 
IgG, and others 
• Starry sky: fine 
granular C3, IgG 
(early in disease) 
• Mesangial: 
mesangial C3 
(week 4-6) 
 
Acute: subepithelial 
humps, disappear by 6th 
week 
 
Garland type: dense 
deposits along capillary 
loops, subepithelial 
Interstitial Nephritis Cellular infiltrates in 
interstitium 
Negative Interrupted BM with 
thickened areas 
Hemolytic Uremic Syndrome Thrombosis of 
glomeruli, arterioles
Negative No deposits 
Nephrotic Syndrome    
Minimal Change Nephrotic 
Syndrome 
 
 Normal 
 
 
Negative Marked foot process 
effacement 
  
Focal and Segmental 
Glomerulosclerosis 
Segmental sclerosis 
of glomeruli 
Negative (may be 
positive for mesangial 
C3, IgM) 
Foot process effacement, 
early hyaline deposition 
 
Membranous Nephropathy All glomeruli 
affected 
Thickened capillary 
walls 
Membrane “spikes” 
Granular IgG or C3 Thickened basement 
membrane 
Electron dense 
subepithelial immune 
deposits 
Spikes  
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Rapidly Progressive 
Glomerulonephritis
ANCA associated vasculitis
 
 
Endocapillary 
proliferation, some 
mesangial 
proliferation, urinary 
space open, focal 
necrosis, crescents 
Proliferation of 
podocytes and 
epithelial cells, 
proliferation of cells 
around Bowman’s 
capsule leads to 
crescent formation
Negative
 
 
 
 
 
 
 
 
 
No deposits 
Anti-GBM disease 
 
Endocapillary 
proliferation, some 
mesangial 
proliferation, urinary 
space open, focal 
necrosis, crescents 
 
Proliferation of 
podocytes and 
epithelial cells, 
proliferation of cells 
around Bowman’s 
capsule leads to 
crescent formation 
Anti-glomerular 
basement membrane 
antibodies (IgG) 
Linear pattern 
 
No deposits 
Transplant Biopsies
Acute Cellular Rejection
 
 
Tubulitis
Endothelialitis 
Humoral Rejection C4d positive staining
Calcineurin Inhibitor Toxicity Concentric 
hyalinosis 
Interstitial Fibrosis
+ Arteriolar IgM Necrosis, smooth 
muscle cell injury 
Table 4. Histopathology Based on Diagnosis and Type of Tissue Study 
11. Conclusion 
Renal biopsy in children is a safe procedure, typically performed percutaneously  
with ultrasound guidance and conscious sedation, and with an 8 to 24 hour period  
of post-procedure observation. Biopsy allows diagnosis of new renal conditions,  
assesses health of the renal parenchyma by defining the extent of injury and potential for 
recovery, and provides the pediatric clinician with valuable information to tailor  
further diagnostic or therapeutic interventions. Surgical renal biopsy by open technique 
or laparoscopic approach is less commonly required for the child with an isolated  
renal condition. The ability to rely on percutaneous biopsy simplifies the typical 
procedure, decreases patient time spent hospitalized or under supervised observation, 
and ultimately provides economy of health care costs. More importantly, by allowing  
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for precise histopathologic diagnosis rather than clinical assessment alone, the use of  
renal biopsy as needed in children helps to expand the understanding of the impact  
and course of certain pediatric renal diseases, their response to therapy, and their 
prognosis. 
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